Trade Summary

1 week ago, Simon Amy, serving as Chief Medical Officer at Beam Therapeutics Inc. (BEAM), sold 6,700 shares at $24.58 per share, for a total transaction value of $164,686.00. Following this transaction, Simon Amy now holds 102,735 shares of BEAM.

This sale represents a 6.00% decrease in Simon Amy's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Wednesday, April 1, 2026 and publicly disclosed via SEC Form 4 filing on Monday, April 6, 2026, 5 days after the trade was made.

Beam Therapeutics Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.